Byproduct, source, and/or special nuclear relations of the special file of the special of the special file of the special	NRC FORM 374						PAGEOFPAG Amendment No. 5				
Pursuant to the Atomic Energy Act of 1924 (Public Law 324), and Tills 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 23, 33, 43, 58, 94, 90, and 70, and in reliance on statements and representations beretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer typroduct, or deliver or transfer such material id energized below; to use such amaterial for the purpose(s) and at the place(s) designed below; or deliver or transfer such material in conciliance with the regulations of the applicable Part(s). This licenses shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act 1954, as amended, and is subject to all below.         Licensee       In accordance with the lefter parted April 28, 2011,         1. Covenant Medical Center, Inc.       In accordance with the lefter parted Saginaw, MI 48602         2. 1447 N, Harrison Saginaw, MI 48602       7. Chemical and/or physical form nuclear material       8. Maximum amount that licensee may possess at any one time under this licensee         A. Any byproduct material permitted by 10 CFR 35.100       B. Any       A. As needed         B. Any byproduct material permitted by 10 CFR 35.300       D. Sealed sources (Implant Model No. 6711 OncoSeed; Mentor Model No. 125SL or 1-125SH and IsoAid LLC., Model IAI-125A)       D. 1.15 curies         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.30											
Litensee       In accordance with the lefter defed         April 28, 2011,       3. License number 21-01492-02 is amended in its entirety to read as follows:         2. 1447 N. Harrison       4. Expiration date December 31, 2014         Saginaw, MI 48602       5. Docket No. 030-02012         Reference No.       6. Byproduct, source, and/or special nuclear material         A. Any byproduct material permitted by 10 CFR 35.100       7. Chemical and/or physical form permitted by 10 CFR 35.100         B. Any byproduct material permitted by 10 CFR 35.200       C. Any         C. Any byproduct material permitted by 10 CFR 35.300       B. Any         D. lodine-125 permitted by 10 CFR 35.300       D. Sealed sources (Implant Sciences Model No. 5500; Medi-Physics/Amersham Model No. F125SH and IsoAid L.L.C., Model IAI-125SI)       D. 1.15 curies         C. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any uptake, dilution and excretion study permitted by 10 CFR 35.300.         D. Any imaging and localization study permitted by 10 CFR 35.300.       D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.	Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified										
1. Covenant Medical Center, Inc.       3. License number 21-01492-02 is amended in its entirety to read as follows:         2. 1447 N. Harrison Saginaw, MI 48602       4. Expiration date December 31, 2014         5. Byproduct, source, and/or special nuclear material       7. Chemical and/or physical form permitted by 10 CFR 35.100       8. Maximum amount that licensee may possess at any one time under this license         A. Any byproduct material permitted by 10 CFR 35.100       B. Any       8. Maximum amount that licensee may possess at any one time under this license         A. Any byproduct material permitted by 10 CFR 35.200       C. Any       C. As needed         D. lodine-125 permitted by 10 CFR 35.300       D. Sealed sources (Implant D. 1.15 curies Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 6711 OncoSeed; Mentor Model No. 6711 OncoSeed; Mentor Model No. 1-125S1 and IsoAid L.L.C., Model IAI-125A)       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any uptake, dilution and excretion study permitted by 10 CFR 35.300.       D. OFR 35.300.         D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.       D. CFR 35.400.       D. CFR 35.400.											
2. 1447 N. Harrison Saginaw, MI 48602       entirety to read as follows:         4. Expiration date December 31, 2014         5. Docket No. 030-02012 Reference No.         6. Byproduct, source, and/or special nuclear material       7. Chemical and/or physical form nuclear material       8. Maximum amount that licensee may possess at any one time under this license         A. Any byproduct material permitted by 10 CFR 35.100       A. Any       A. As needed         B. Any byproduct material permitted by 10 CFR 35.200       B. Any       B. As needed         C. Any byproduct material permitted by 10 CFR 35.300       D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 1425SL or I-125SH and IsoAid L.L.C., Model IAI-125A)       D. 1.15 curies         E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any uptake, dilution and excretion study permitted by 10 CFR 35.300.         D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.       C. Any CFR 35.400.					April 28, 2011,						
Saginaw, MI 48602       5. Docket No. 030-02012 Reference No.         6. Byproduct, source, and/or special nuclear material       7. Chemical and/or physical form permitted by 10 CFR 35.100       8. Maximum amount that licensee may possess at any one time under this license         A. Any byproduct material permitted by 10 CFR 35.100       A. Any       A. As needed         B. Any byproduct material permitted by 10 CFR 35.200       B. Any       B. As needed         C. Any byproduct material permitted by 10 CFR 35.300       D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 671 OncoSeed; Mentor Model No. 1-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)       D. 1.15 curies         E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any uptake, dilution and excretion study permitted by 10 CFR 35.200.         C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.       D. OFR 35.400.	1. Cove	anant Medical Center, Inc.		ļ	entirety to read as follows:						
Reference No.         6. Byproduct, source, and/or special nuclear material       7. Chemical and/or physical form       8. Maximum amount that licensee may possess at any one time under this licensee         A. Any byproduct material permitted by 10 CFR 35.100       A. Any       A. As needed         B. Any byproduct material permitted by 10 CFR 35.200       B. Any       B. As needed         C. Any byproduct material permitted by 10 CFR 35.200       C. Any       C. As needed         D. lodine-125 permitted by 10 CFR 35.300       D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 6710 OncoSeed; Mentor Model No. 1/125SL or l-125SL and IsoAid L.L.C., Model IAI-125A)       D. 1.15 curies         E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any uptake, dilution and excretion study permitted by 10 CFR 35.200.         C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.       D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.				ļ	4. Expiration date December 31, 2014						
nuclear material       possess at any one time under this license         A. Any byproduct material permitted by 10 CFR 35.100       A. Any       A. As needed         B. Any byproduct material permitted by 10 CFR 35.200       B. Any       B. As needed         C. Any byproduct material permitted by 10 CFR 35.300       D. Any       C. Any       C. As needed         D. lodine-125 permitted by 10       D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 125SL or I-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)       D. 1.15 curies         E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any imaging and localization study permitted by 10 CFR 35.200.         C. Any manual brachytherapy procedure permitted by 10 CFR 35.400.       D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.	Sagir	naw, MI 48602				02012	2				
permitted by 10 CFR 35.100         B. Any byproduct material permitted by 10 CFR 35.200       B. Any       B. As needed         C. Any byproduct material permitted by 10 CFR 35.300       C. Any       C. As needed         D. Iodine-125 permitted by 10 CFR 35.300       D. Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 6711			mical and/or ph	iysical form	possess at any one time under this						
<ul> <li>permitted by 10 CFR 35.200</li> <li>C. Any byproduct material permitted by 10 CFR 35.300</li> <li>D. lodine-125 permitted by 10 CFR 35.300</li> <li>D. lodine-125 permitted by 10 CFR 35.400</li> <li>D. Sealed sources (Implant D. 1.15 curies Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 1-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)</li> <li>E. Any byproduct material permitted by 10 CFR 31.11</li> <li>F. Prepackaged Kits E. 5 millicuries</li> <li>9. Authorized Use:</li> <li>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</li> <li>B. Any imaging and localization study permitted by 10 CFR 35.200.</li> <li>C. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</li> </ul>			A.	Any		Α.	As needed				
permitted by 10 CFR 35.300         D.       lodine-125 permitted by 10 CFR 35.400       D.       Sealed sources (Implant Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. I-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)       D.       1.15 curies         E.       Any byproduct material permitted by 10 CFR 31.11       E.       Prepackaged Kits       E.       5 millicuries         9.       Authorized Use:       A.       Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B.       Any imaging and localization study permitted by 10 CFR 35.200.       C.       Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.       D.       Any manual brachytherapy procedure permitted by 10 CFR 35.400.		• • •	Β.	Any		В.	As needed				
CFR 35.400       Sciences Model No. 3500; Medi-Physics/Amersham Model No. 6711 OncoSeed; Mentor Model No. 1-125SL or I-125SH and IsoAid L.L.C., Model IAI-125A)         E. Any byproduct material permitted by 10 CFR 31.11       E. Prepackaged Kits       E. 5 millicuries         9. Authorized Use:       A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.       B. Any imaging and localization study permitted by 10 CFR 35.200.         C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.       D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.			<b>C</b> .	Any		C.	As needed				
<ul> <li>permitted by 10 CFR 31.11</li> <li>9. Authorized Use:</li> <li>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</li> <li>B. Any imaging and localization study permitted by 10 CFR 35.200.</li> <li>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</li> <li>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</li> </ul>			<b>D.</b>	Sciences M Medi-Physic Model No. 6 Mentor Mod or I-125SH	lodel No. 3500; cs/Amersham 6711 OncoSeed; del No. I-125SL and IsoAid	D.	1.15 curies				
<ul> <li>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</li> <li>B. Any imaging and localization study permitted by 10 CFR 35.200.</li> <li>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</li> <li>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</li> </ul>			E.	Prepackage	ed Kits	Ε.	5 millicuries				
<ul><li>B. Any imaging and localization study permitted by 10 CFR 35.200.</li><li>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</li><li>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</li></ul>	9. Aut	thorized Use:	*		A			-			
<ul><li>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</li><li>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</li></ul>	Α.	A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.									
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.	В.	B. Any imaging and localization study permitted by 10 CFR 35.200.									
	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.										
E. <u>In vitro</u> studies.	D.	Any manual brachytherapy r	procedu	ure permitted	by 10 CFR 35.400	).					
	E.	<u>In vitro</u> studies.									

NR	C FOF	M 374A U.S. NUCLEAR REGU	ILATORY COMMISSION	*F	PAGE	2	of	3	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET			License Number 21-01492-02						
		-	Docket or Reference Number 030-02012						
			Amendment No. 59						
			CONDITIONS	<u> </u>					
10.	A.								r
	Β.	Licensed material, excluding iodine-131 for thyroid carcinoma therapies may be used at the licensee's facilities located at 5400 Mackinaw Road, Saginaw Michigan.							
	C.	Licensed materials 6.A. and 6.B. may be used at the licensee's facilities located at 318 W. Wright Avenue, Shepherd, Michigan.							
	D.	License materials listed in Subitem 6.B. may be used at the licensee's facilities located at 4884 Berl Drive, Saginaw, Michigan.							
11.	The Radiation Safety Officer for this license is Mark Robert Ludka, M.D.								
12. Licensed material is only authorized for use by, or under the supervision of:									
	Α.	Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.							
	в.	The following individuals are authorized users for medical uses:							
		Authorized User	Material and	d Use					
		Joseph E. Talbot, M.D.	10 CFR 35.	100, 35.200 and 35.300	).				
		Scott E. Cheney, M.D.	10 CFR 35.	100 and 35.200.					
		Sanjay J. Talati, M.D.	10 CFR 35.	100 and 35.200.					
		George F. Ascherl, M.D.	10 CFR 35.	100, 35.200 and 35.300	).				
		Harvey Yee, M.D.	10 CFR 35.	100, 35.200 and 35.300	).				
		C.E. Mueller, M.D.	10 CFR 35.	100, 35.200, 35.300 and	d 31.1	1.			
		Robert B. Saltzman, M.D.	10 CFR 35.	100, 35.200, 35.300 and	<b>d 3</b> 1.1	1.			
		Mark Robert Ludka, M.D.	10 CFR 35.	100, 35.200, 35.300 and	31.1	1.			
		Kristin M. Nelsen, M.D.	10 CFR 35.	100, 35.200, and 31.11.					
		Rajnikant H. Mehta, M.D.	10 CFR 35.4	400.					
		Rajesh P. Kotecha, M.D.	10 CFR 35.4	400.					
		Paul G. Kocheril, M.D.	10 CFR 35.4	400.					
		James F. Littles, M.D.	10 CFR 35.4	400.					

NRC FORM 374A	U.S. NUCLEAR REGULATORY	COMMISSION		PAGE	3	of	3	PAGES
		License Number 21-01492-02						
MATERIALS LICENSE SUPPLEMENTARY SHEET			Docket or Reference Numbe 030-02012	r				
			Amendment No. 59			<u> </u>		
			[					
Sigri	d E. Messana, D.O.	10 CFR 35	.100, 35.200, and 31.1	11.				
Chiro	deep Bhutani, M.D.	10 CFR 35	.100, 35.200 and 35.3	00.				
Sam	basiva Kottamasu, M.D.	10 CFR 35	.100, 35.200, 35.300 a	and 31.	11.			
Ram	esh Vedula, M.D.	10 CFR 35	.400.					
Sulta	an Bhimani, M.D.	10 CFR 35	.100, 35.200, and 31.1	11.				
Ram	K. Gadam, M.D.	10 CFR 35	.100, 35.200, 35.300 a	and 35.	400			
Stev	e Min, D.O.	10 CFR 35	.100, 35.200, and 35.3	300				
<b>K.</b> K.	Ravindran, M.D.	10 CFR 35	.200.					
Ume	sh Badami, M.D.	10 CFR 35	.200.					

- 13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Materials."
- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated September 24, 2004.
  - B. Letters dated August 21, 2006, December 4, 2006, July 31, 2009 and July 13, 2010.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Juge L. Sermons By

Toye L. Simmons Materials Licensing Branch Region IIII

Date JUL 1 5 2011